Dr J.P. Capo’ Jr,
Internal Medicine Associates of Atlanta, Executive Health and Research, 5505 Peachtree-Dunwoody Road, Suite 650, Atlanta, GA 30342, USA
Tel.: + 1 404 256 1104
Fax: + 1 404 256 0321
Email: [email protected]

Disclosure
Dr Capo’ is a Consultant/Advisor for Astellas, Boehringer Mannheim Pharmaceuticals, Cephalon Inc. and GlaxoSmithKline; is a Speaker for Astellas, GlaxoSmithKline, Reliant Pharmaceuticals and Schering Plough Corporation; is an Investigator for Abbott, Akros, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Lilly, Mankind, Merck, Novartis, NovoNordisk, Pfizer Inc., Solvay, Takeda and TAP; and is a Lecturer for Pri Med. Dr Laramée is a Consultant/Advisor and Investigator for Astellas and GlaxoSmithKline. Dr Lucente has received research support in the past from Astellas and presently receives honoraria for lectures. Dr Fakhoury is an employee of Astellas Pharma US Inc. Dr Forero-Schwanhaeuser is an employee of GlaxoSmithKline.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Summary

Objective: The primary goal of overactive bladder (OAB) treatment is to reduce symptoms and improve health-related quality of life (HRQoL). Although trials open enrolment to everyone, most OAB studies feature Caucasians. Here we present Hispanic data.

Methods: VESIcare^® Open-Label Trial was a 12-week, open-label, flexible-dosing study in patients with OAB symptoms for ≥ 3 months. All patients started on solifenacin 5 mg/day, with a dosing option of 5 or 10 mg/day at weeks 4 and 8. Three patient-reported outcome (PRO) measures assessed symptom improvement and treatment satisfaction: the Patient Perception of Bladder Condition (PPBC) scale, a Visual Analogue Scale (VAS), the Overactive Bladder Questionnaire (OAB-q).

Results: 94/2205 patients in the full population were Hispanic. Urgency was most frequently reported at baseline (93.6%), followed by frequency (91.5%), nocturia (84.0%) and urge incontinence (UI) (67.0%). Frequency was reported as the most bothersome symptom (MBS) by a higher proportion of Hispanics than the full population (40.4% vs. 28.1%). UI was reported as the MBS by a smaller proportion of Hispanics (18.1% vs. 27.3%). Patients reporting moderate-to-severe problems related to bladder condition at baseline reported improvement to ‘some minor problems’ at week 12. Over 72.0% of patients experienced PPBC score improvement. Both groups reported significant improvements in urgency, UI, frequency and nocturia on the VAS (all p < 0.001) and all OAB-q domains (all p < 0.001) at week 12.

Conclusion: Although numbers were small, Hispanics receiving solifenacin for OAB reported improvement from baseline in symptom bother and HRQoL, as assessed by three independent PRO measures.

References

1 Abrams P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006; 25: 293.
10.1002/nau.20251
PubMed Web of Science® Google Scholar
2 Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455–63.
10.1111/j.1524-4733.2004.74008.x
PubMed Web of Science® Google Scholar
3 Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 1044–50.
10.1016/S0090-4295(01)00986-4
CAS PubMed Web of Science® Google Scholar
4 Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006; 68 (2 Suppl.): 17–28.
10.1016/j.urology.2006.05.044
PubMed Web of Science® Google Scholar
5 Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006; 68 (2 Suppl.): 38–48.
10.1016/j.urology.2006.05.043
PubMed Web of Science® Google Scholar
6 Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; CD003193.
CAS PubMed Google Scholar
7 Lewis-Fernandez R, Das AK, Alfonso C et al. Depression in US Hispanics: diagnostic and management considerations in family practice. J Am Board Fam Pract 2005; 18: 282–96.
10.3122/jabfm.18.4.282
PubMed Web of Science® Google Scholar
8 Ramirez AG, Villarreal R, Suarez L, Flores ET. The emerging Hispanic population: a foundation for cancer prevention and control. J Natl Cancer Inst Monogr 1995; 18: 1–9.
PubMed Google Scholar
9 Bernstein R. Nation's Population One-third Minority. Washington, DC: U.S. Census Bureau News, U.S. Department of Commerce. http://www.census.gov/Press-Release/www/releases/archives/population/006808.html (accessed March 2007).
Google Scholar
10 U.S. Census Bureau. The Hispanic Population in the United States, 2004, Detailed Tables. http://www.census.gov/population/www/socdemo/hispanic/cps2004.html (accessed March 2007).
Google Scholar
11 Bergman M. Census bureau projects tripling of Hispanic and Asian populations in 50 years; non-Hispanic Whites may drop to half of total population. Washington, DC: U.S. Census Bureau News, U.S. Department of Commerce. http://www.census.gov/Press-Release/www/releases/archives/population/001720.html (accessed March 2007).
Google Scholar
12 Duong TH, Korn AP. A comparison of urinary incontinence among African American, Asian, Hispanic, and white women. Am J Obstet Gynecol 2001; 184: 1083–6.
10.1067/mob.2001.115221
CAS PubMed Web of Science® Google Scholar
13 Sampselle CM, Harlow SD, Skurnick J et al. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol 2002; 100: 1230–8.
10.1016/S0029-7844(02)02241-X
PubMed Web of Science® Google Scholar
14 Espino DV, Palmer RF, Miles TP et al. Prevalence and severity of urinary incontinence in elderly Mexican-American women. J Am Geriatr Soc 2003; 51: 1580–6.
10.1046/j.1532-5415.2003.51503.x
PubMed Web of Science® Google Scholar
15 Mattox TF, Bhatia, NN. The prevalence of urinary incontinence or prolapse among white and Hispanic women. Am J Obstet Gynecol 1996; 174: 646–8.
10.1016/S0002-9378(96)70443-X
CAS PubMed Web of Science® Google Scholar
16 Mallett V, Burks D, Garely A, Smith N. Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. Curr Med Res Opin 2007; 23: 821–31.
10.1185/030079907X178847
CAS PubMed Web of Science® Google Scholar
17 Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006; 28: 1935–46.
10.1016/j.clinthera.2006.11.010
CAS PubMed Web of Science® Google Scholar
18 Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079–86.
10.1016/j.eururo.2006.01.007
PubMed Web of Science® Google Scholar
19 Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140–5.
10.1016/S0022-5347(05)66095-8
CAS PubMed Web of Science® Google Scholar
20 Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237–42.
10.1016/S0090-4295(03)00356-X
PubMed Web of Science® Google Scholar
21 Leung HY, Yip SK, Cheon C et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 2002; 90: 375–80.
10.1046/j.1464-410X.2002.02905.x
CAS PubMed Web of Science® Google Scholar
22 Stach-Lempinen B, Kujansuu E, Laippala P, Metsanoja R. Visual Analogue Scale, urinary incontinence severity score and 15 D-psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol 2001; 35: 476–83.
10.1080/003655901753367587
CAS PubMed Web of Science® Google Scholar
23 Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563–74.
10.1023/A:1016370925601
CAS PubMed Web of Science® Google Scholar
24 Matza LS, Zyczynski TM, Bavendam T. A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep 2004; 5: 336–42.
10.1007/s11934-004-0079-6
PubMed Google Scholar
25 Matza LS, Thompson CL, Krasnow J et al. Test–retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215–25.
10.1002/nau.20110
PubMed Web of Science® Google Scholar
26 Coyne KS, Matza LS, Thompson CL et al. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006; 176: 627–32.
10.1016/j.juro.2006.03.088
PubMed Web of Science® Google Scholar
27 Heit M, Blackwell L, Kelly S. A model for explaining differences in incontinence care seeking (Medics project). ICS 2004, Paris, France. Abstract 420.
Google Scholar

Citing Literature

All articles

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare^® Open-Label Trial

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare® Open-Label Trial

Summary

References

Citing Literature

References

Related

Information

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare^® Open-Label Trial